CVS Health Corporation (NYSE:CVS) has been under scrutiny recently due to rumors of a potential restructuring that may include the divestment of its major business units. With CVS stock currently trading around its 50-day moving average, there has been an uptrend in shares, reflecting a potential shift in market sentiment. This article explores the recent developments affecting CVS stock performance and whether these factors signal a buy, hold, or sell opportunity for investors.

What’s Fueling the CVS Restructuring Rumors?

The stock of CVS Health has been facing headwinds due to ongoing discussions around strategic changes to improve shareholder value. Recently, there were reports suggesting that CVS may consider spinning off its Caremark pharmacy benefit management (PBM) division or even its Aetna health insurance business. Such a move would represent a significant shift in the company’s core operations and could potentially lead to a rise in CVS stock value as a result of increased focus and efficiency within each business segment.

The speculation about possible restructuring has led to a 1.1% increase in CVS stock, which closed at $62.24 recently. The market seems optimistic about the company’s proactive approach to addressing performance challenges and maximizing value for shareholders. However, the exact nature and feasibility of any potential spinoffs remain unclear, leaving room for speculation and volatility in CVS stock’s price.

CVS and Legal Challenges: The FTC Lawsuit

Beyond its internal restructuring, CVS is also facing legal challenges that have raised concerns among investors. The Federal Trade Commission (FTC) has issued notices against the PBM businesses of CVS Health, Cigna (NYSE:CI), and UnitedHealth (NYSE:UNH) over alleged price manipulation in insulin drugs. CVS Caremark, along with Cigna’s Express Scripts and UnitedHealth’s OptumRx, collectively hold over 80% of the PBM market share.

The FTC claims that these companies have engaged in anti-competitive and unfair rebating practices, leading to inflated insulin prices and hindering affordable access to the drug. Following this notice, some investors are pushing for CVS to restructure its business, as breaking up certain segments could mitigate risks associated with the lawsuit and potentially unlock value.

Performance Against Peers and Industry Trends

Year-to-date, CVS Health stock has witnessed a notable decline of 21.1%, underperforming both the retail sector’s growth of 19.6% and the S&P 500’s 20% rise. However, this downward trend is consistent with the broader industry struggles. For example, Walgreens Boots Alliance (NASDAQ:WBA) has experienced a 66.7% plunge, and Herbalife (NYSE:HLF) has dropped by 55.3%. Despite the decline, CVS remains a critical player in the industry, and any strategic moves made to streamline its business could present an opportunity for recovery.

Silver Linings and Future Prospects for CVS

Bright Roadmap for 2025

CVS Health has a clear growth plan, leveraging acquisitions like Signify Health and Oak Street Health to enhance its service offerings. Notably, Signify currently serves twice as many Aetna members, and Oak Street clinics have tripled their Aetna membership. This integrated approach is expected to pay off by the 2025 enrollment period, particularly with co-branded Aetna and Oak Street plans that aim to expand member reach.

In June 2024, CVS submitted its bids for the 2025 Medicare Advantage plans, expecting prudent pricing to lead to improved utilization and margin recovery by up to 200 basis points. If successful, this plan will align with CVS Health’s goal of achieving its multi-year target margins of 4-5%.

Digital Growth Strategy

CVS is also doubling down on its digital transformation to automate processes, reduce costs, and improve customer experience. By removing barriers to digital adoption, CVS has enhanced its ability to offer services such as pharmacy refills and scheduling for immunizations online. The company reported that nearly 60 million unique customers used its digital platform in Q2 2024 for appointments, prescription management, and wellness product purchases.

The ongoing innovation and technological investment place CVS Health in a strong position to expand customer engagement, increase revenue, and enhance overall business growth.

CVS Stock Valuation: Is It Worth the Price?

Currently, CVS Health’s forward 12-month price-to-earnings (P/E) ratio stands at 8.78x, which is higher than the industry average of 7.95x. This premium valuation, especially compared to its peers like Walgreens Boots (4.91x) and Herbalife (4.09x), suggests that investors may be paying a higher price relative to the company’s expected earnings growth. With a Value Score of “A,” CVS stock does present an attractive profile, but its current valuation might deter value-focused investors from initiating new positions.

Final Thoughts: Is CVS a Buy, Hold, or Sell?

CVS stock’s recent surge above its 50-day moving average indicates potential positive momentum, but it remains below the 200-day moving average, suggesting that resistance or pullbacks could still occur. Given the current stretched valuation and uncertain future, investing in CVS Health at this stage could be risky. Investors holding CVS stock might consider selling to capitalize on any potential short-term gains while the company navigates through restructuring and legal challenges.

In conclusion, while CVS Health has bright spots on its roadmap, its current performance and valuation suggest a cautious approach for potential investors. As the company works on enhancing shareholder value and navigating its evolving business landscape, monitoring market movements and future earnings reports will be critical for informed investment decisions.

Featured Image:  Megapixl @Jetcityimage

Please See Disclaimer